Heron Therapeutics Inc (HRTX) has disclosed a new risk, in the Debt & Financing category.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
He notes that restrictive covenants in Heron Therapeutics Inc.’s working capital facility and 2031 convertible notes could limit additional borrowing, constrain strategic actions like mergers or investments, and reduce financial flexibility for growth. Any breach of minimum cash, revenue, or EBITDA covenants could trigger defaults and accelerate repayment, potentially straining liquidity and operational stability.
Overall, Wall Street has a Moderate Buy consensus rating on HRTX stock based on 2 Buys.
To learn more about Heron Therapeutics Inc’s risk factors, click here.